Roche's Lung-Cancer Drug Alecensa Gets New FDA Approval
By Adria Calatayud
Roche Holding's Alecensa lung-cancer drug received a new approval from the U.S. Food and Drug Administration as an additional treatment for patients who have undergone surgery to remove their tumor.
The Swiss pharmaceutical giant said Friday that the approval was based on a late-stage trial that showed Alecensa reduced the risk of disease recurrence or death in patients with a type of early-stage resected nonsmall cell lung cancer.
The drug is currently approved in more than 100 countries--including the U.S.--as an initial and second-line treatment for that kind of lung cancer, the company said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
April 19, 2024 01:29 ET (05:29 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing